BioPartners GmbH Presents Three Year Safety and Efficacy Data for Sustained Release Recombinant Human Growth Hormone (LB03002) at ESPE 2008
BAAR, Switzerland--(BUSINESS WIRE)--Biopartners GmbH today presented three year safety and efficacy trial data in children with growth hormone deficiency (GHD) for its once-a-week, sustained release recombinant human growth hormone (SR-hGH; LB03002) at the Annual Meeting of the European Society for Paediatric Endocrinology in Istanbul.